Cargando…
Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease characterized by the gradual loss of upper and lower motor neurons that leads to progressive muscle atrophy and weakness. Edaravone, a free-radical scavenger, was approved as an ALS treatment in 2015 in South Korea...
Autores principales: | Park, Jin-Mo, Park, Donghwi, Kim, Hyung-Jun, Park, Jin-Sung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281019/ https://www.ncbi.nlm.nih.gov/pubmed/35836136 http://dx.doi.org/10.1186/s12883-022-02788-x |
Ejemplares similares
-
Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
por: Park, Jin-Mo, et al.
Publicado: (2019) -
Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis
por: Okada, Masamitsu, et al.
Publicado: (2018) -
Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis
por: Jayasinghe, Maleesha, et al.
Publicado: (2022) -
Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone
por: Kakimoto, Asako, et al.
Publicado: (2021) -
Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
por: Cho, HaEun, et al.
Publicado: (2020)